<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="2004-08-16" modified="2020-10-07" version="185">
<accession>Q9NQC7</accession>
<accession>O94934</accession>
<accession>Q7L3N6</accession>
<accession>Q96EH0</accession>
<accession>Q9NZX9</accession>
<name>CYLD_HUMAN</name>
<protein>
<recommendedName>
<fullName>Ubiquitin carboxyl-terminal hydrolase CYLD</fullName>
<ecNumber evidence="25 34 36">3.4.19.12</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Deubiquitinating enzyme CYLD</fullName>
</alternativeName>
<alternativeName>
<fullName>Ubiquitin thioesterase CYLD</fullName>
</alternativeName>
<alternativeName>
<fullName>Ubiquitin-specific-processing protease CYLD</fullName>
</alternativeName>
</protein>
<gene>
<name type="primary" evidence="39 43">CYLD</name>
<name type="synonym">CYLD1</name>
<name type="synonym" evidence="38">KIAA0849</name>
<name type="ORF">HSPC057</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="2000" name="Nat. Genet." volume="25" first="160" last="165">
<title>Identification of the familial cylindromatosis tumor suppressor gene.</title>
<authorList>
<person name="Bignell G.R."/>
<person name="Brown C."/>
<person name="Biggs P.J."/>
<person name="Lakhani S.R."/>
<person name="Jones C."/>
<person name="Hansen J."/>
<person name="Blair E."/>
<person name="Hofmann B."/>
<person name="Siebert R."/>
<person name="Turner G."/>
<person name="Evans D.G."/>
<person name="Schrander-Stumpel C."/>
<person name="Beemer F.A."/>
<person name="Van Den Ouweland A."/>
<person name="Halley D."/>
<person name="Delpech B."/>
<person name="Cleveland M.G."/>
<person name="Leigh I."/>
<person name="Leisti J."/>
<person name="Rasmussen S."/>
<person name="Wallace M.R."/>
<person name="Fenske C."/>
<person name="Banerjee P."/>
<person name="Oiso N."/>
<person name="Chaggar R."/>
<person name="Merrett S."/>
<person name="Leonard N."/>
<person name="Huber M."/>
<person name="Hohl D."/>
<person name="Chapman P."/>
<person name="Burn J."/>
<person name="Swift S."/>
<person name="Smith A."/>
<person name="Ashworth A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="10835629"/>
<dbReference type="DOI" id="10.1038/76006"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>INVOLVEMENT IN FAMILIAL CYLINDROMATOSIS</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1998" name="DNA Res." volume="5" first="355" last="364">
<title>Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.</title>
<authorList>
<person name="Nagase T."/>
<person name="Ishikawa K."/>
<person name="Suyama M."/>
<person name="Kikuno R."/>
<person name="Hirosawa M."/>
<person name="Miyajima N."/>
<person name="Tanaka A."/>
<person name="Kotani H."/>
<person name="Nomura N."/>
<person name="Ohara O."/>
</authorList>
<dbReference type="PubMed" id="10048485"/>
<dbReference type="DOI" id="10.1093/dnares/5.6.355"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="3">
<citation type="journal article" date="2002" name="DNA Res." volume="9" first="99" last="106">
<title>Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.</title>
<authorList>
<person name="Nakajima D."/>
<person name="Okazaki N."/>
<person name="Yamakawa H."/>
<person name="Kikuno R."/>
<person name="Ohara O."/>
<person name="Nagase T."/>
</authorList>
<dbReference type="PubMed" id="12168954"/>
<dbReference type="DOI" id="10.1093/dnares/9.3.99"/>
</citation>
<scope>SEQUENCE REVISION</scope>
</reference>
<reference key="4">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)</scope>
<source>
<tissue>Uterus</tissue>
</source>
</reference>
<reference key="5">
<citation type="journal article" date="2000" name="Genome Res." volume="10" first="1546" last="1560">
<title>Cloning and functional analysis of cDNAs with open reading frames for 300 previously undefined genes expressed in CD34+ hematopoietic stem/progenitor cells.</title>
<authorList>
<person name="Zhang Q.-H."/>
<person name="Ye M."/>
<person name="Wu X.-Y."/>
<person name="Ren S.-X."/>
<person name="Zhao M."/>
<person name="Zhao C.-J."/>
<person name="Fu G."/>
<person name="Shen Y."/>
<person name="Fan H.-Y."/>
<person name="Lu G."/>
<person name="Zhong M."/>
<person name="Xu X.-R."/>
<person name="Han Z.-G."/>
<person name="Zhang J.-W."/>
<person name="Tao J."/>
<person name="Huang Q.-H."/>
<person name="Zhou J."/>
<person name="Hu G.-X."/>
<person name="Gu J."/>
<person name="Chen S.-J."/>
<person name="Chen Z."/>
</authorList>
<dbReference type="PubMed" id="11042152"/>
<dbReference type="DOI" id="10.1101/gr.140200"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 397-956</scope>
<source>
<tissue>Umbilical cord blood</tissue>
</source>
</reference>
<reference key="6">
<citation type="journal article" date="2003" name="Nature" volume="424" first="793" last="796">
<title>CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.</title>
<authorList>
<person name="Trompouki E."/>
<person name="Hatzivassiliou E."/>
<person name="Tsichritzis T."/>
<person name="Farmer H."/>
<person name="Ashworth A."/>
<person name="Mosialos G."/>
</authorList>
<dbReference type="PubMed" id="12917689"/>
<dbReference type="DOI" id="10.1038/nature01803"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH IKBKG/NEMO</scope>
<scope>MUTAGENESIS OF CYS-601</scope>
</reference>
<reference key="7">
<citation type="journal article" date="2003" name="Nature" volume="424" first="797" last="801">
<title>Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.</title>
<authorList>
<person name="Brummelkamp T.R."/>
<person name="Nijman S.M.B."/>
<person name="Dirac A.M.G."/>
<person name="Bernards R."/>
</authorList>
<dbReference type="PubMed" id="12917690"/>
<dbReference type="DOI" id="10.1038/nature01811"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH IKBKG/NEMO</scope>
<scope>MUTAGENESIS OF CYS-601</scope>
</reference>
<reference key="8">
<citation type="journal article" date="2003" name="Nature" volume="424" first="801" last="805">
<title>The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.</title>
<authorList>
<person name="Kovalenko A."/>
<person name="Chable-Bessia C."/>
<person name="Cantarella G."/>
<person name="Israeel A."/>
<person name="Wallach D."/>
<person name="Courtois G."/>
</authorList>
<dbReference type="PubMed" id="12917691"/>
<dbReference type="DOI" id="10.1038/nature01802"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH IKBKG/NEMO AND TRAF2</scope>
<scope>MUTAGENESIS OF SER-457 AND HIS-871</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2003" name="J. Exp. Med." volume="198" first="1959" last="1964">
<title>The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.</title>
<authorList>
<person name="Regamey A."/>
<person name="Hohl D."/>
<person name="Liu J.W."/>
<person name="Roger T."/>
<person name="Kogerman P."/>
<person name="Toftgaard R."/>
<person name="Huber M."/>
</authorList>
<dbReference type="PubMed" id="14676304"/>
<dbReference type="DOI" id="10.1084/jem.20031187"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH TRIP</scope>
</reference>
<reference key="10">
<citation type="journal article" date="2005" name="Mol. Cell. Biol." volume="25" first="3886" last="3895">
<title>Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation.</title>
<authorList>
<person name="Reiley W."/>
<person name="Zhang M."/>
<person name="Wu X."/>
<person name="Granger E."/>
<person name="Sun S.C."/>
</authorList>
<dbReference type="PubMed" id="15870263"/>
<dbReference type="DOI" id="10.1128/mcb.25.10.3886-3895.2005"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH TRAF2</scope>
<scope>ACTIVITY REGULATION</scope>
<scope>MUTAGENESIS OF SER-418; SER-422; SER-432; SER-436; SER-439; SER-441 AND SER-444</scope>
<scope>PHOSPHORYLATION AT SER-418</scope>
</reference>
<reference key="11">
<citation type="journal article" date="2007" name="Proc. Natl. Acad. Sci. U.S.A." volume="104" first="8869" last="8874">
<title>The tumor suppressor CYLD regulates entry into mitosis.</title>
<authorList>
<person name="Stegmeier F."/>
<person name="Sowa M.E."/>
<person name="Nalepa G."/>
<person name="Gygi S.P."/>
<person name="Harper J.W."/>
<person name="Elledge S.J."/>
</authorList>
<dbReference type="PubMed" id="17495026"/>
<dbReference type="DOI" id="10.1073/pnas.0703268104"/>
</citation>
<scope>FUNCTION</scope>
<scope>MUTAGENESIS OF CYS-601</scope>
<scope>INTERACTION WITH PLK1</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="2008" name="EMBO Rep." volume="9" first="930" last="936">
<title>The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response.</title>
<authorList>
<person name="Friedman C.S."/>
<person name="O'Donnell M.A."/>
<person name="Legarda-Addison D."/>
<person name="Ng A."/>
<person name="Cardenas W.B."/>
<person name="Yount J.S."/>
<person name="Moran T.M."/>
<person name="Basler C.F."/>
<person name="Komuro A."/>
<person name="Horvath C.M."/>
<person name="Xavier R."/>
<person name="Ting A.T."/>
</authorList>
<dbReference type="PubMed" id="18636086"/>
<dbReference type="DOI" id="10.1038/embor.2008.136"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBUNIT</scope>
<scope>INTERACTION WITH DDX58; MAVS; TBK1 AND IKKE</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2008" name="J. Biol. Chem." volume="283" first="8802" last="8809">
<title>The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration.</title>
<authorList>
<person name="Gao J."/>
<person name="Huo L."/>
<person name="Sun X."/>
<person name="Liu M."/>
<person name="Li D."/>
<person name="Dong J.T."/>
<person name="Zhou J."/>
</authorList>
<dbReference type="PubMed" id="18222923"/>
<dbReference type="DOI" id="10.1074/jbc.m708470200"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="15">
<citation type="journal article" date="2010" name="Blood" volume="115" first="4130" last="4137">
<title>CYLD regulates angiogenesis by mediating vascular endothelial cell migration.</title>
<authorList>
<person name="Gao J."/>
<person name="Sun L."/>
<person name="Huo L."/>
<person name="Liu M."/>
<person name="Li D."/>
<person name="Zhou J."/>
</authorList>
<dbReference type="PubMed" id="20194890"/>
<dbReference type="DOI" id="10.1182/blood-2009-10-248526"/>
</citation>
<scope>FUNCTION</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2010" name="EMBO J." volume="29" first="131" last="144">
<title>CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.</title>
<authorList>
<person name="Wickstrom S.A."/>
<person name="Masoumi K.C."/>
<person name="Khochbin S."/>
<person name="Fassler R."/>
<person name="Massoumi R."/>
</authorList>
<dbReference type="PubMed" id="19893491"/>
<dbReference type="DOI" id="10.1038/emboj.2009.317"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH HDAC6; BCL3 AND MICROTUBULES</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2010" name="Mol. Cell" volume="37" first="607" last="619">
<title>Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.</title>
<authorList>
<person name="Tauriello D.V."/>
<person name="Haegebarth A."/>
<person name="Kuper I."/>
<person name="Edelmann M.J."/>
<person name="Henraat M."/>
<person name="Canninga-van Dijk M.R."/>
<person name="Kessler B.M."/>
<person name="Clevers H."/>
<person name="Maurice M.M."/>
</authorList>
<dbReference type="PubMed" id="20227366"/>
<dbReference type="DOI" id="10.1016/j.molcel.2010.01.035"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH DVL1 AND DVL3</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-418 AND SER-422</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="19">
<citation type="journal article" date="2014" name="J. Proteomics" volume="96" first="253" last="262">
<title>An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.</title>
<authorList>
<person name="Bian Y."/>
<person name="Song C."/>
<person name="Cheng K."/>
<person name="Dong M."/>
<person name="Wang F."/>
<person name="Huang J."/>
<person name="Sun D."/>
<person name="Wang L."/>
<person name="Ye M."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="24275569"/>
<dbReference type="DOI" id="10.1016/j.jprot.2013.11.014"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-387</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="20">
<citation type="journal article" date="2014" name="Nat. Commun." volume="5" first="4585" last="4585">
<title>The deubiquitinating enzyme CYLD controls apical docking of basal bodies in ciliated epithelial cells.</title>
<authorList>
<person name="Eguether T."/>
<person name="Ermolaeva M.A."/>
<person name="Zhao Y."/>
<person name="Bonnet M.C."/>
<person name="Jain A."/>
<person name="Pasparakis M."/>
<person name="Courtois G."/>
<person name="Tassin A.M."/>
</authorList>
<dbReference type="PubMed" id="25134987"/>
<dbReference type="DOI" id="10.1038/ncomms5585"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>INTERACTION WITH CEP350</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2002" name="J. Invest. Dermatol." volume="119" first="527" last="531">
<title>Phenotype diversity in familial cylindromatosis: a frameshift mutation in the tumor suppressor gene CYLD underlies different tumors of skin appendages.</title>
<authorList>
<person name="Poblete Gutierrez P."/>
<person name="Eggermann T."/>
<person name="Hoeller D."/>
<person name="Jugert F.K."/>
<person name="Beermann T."/>
<person name="Grussendorf-Conen E.-I."/>
<person name="Zerres K."/>
<person name="Merk H.F."/>
<person name="Frank J."/>
</authorList>
<dbReference type="PubMed" id="12190880"/>
<dbReference type="DOI" id="10.1046/j.1523-1747.2002.01839.x"/>
</citation>
<scope>INVOLVEMENT IN FCYL</scope>
<scope>INVOLVEMENT IN BRSS</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2003" name="Clin. Exp. Dermatol." volume="28" first="539" last="541">
<title>Identification of a recurrent mutation in the CYLD gene in Brooke-Spiegler syndrome.</title>
<authorList>
<person name="Scheinfeld N."/>
<person name="Hu G."/>
<person name="Gill M."/>
<person name="Austin C."/>
<person name="Celebi J.T."/>
</authorList>
<dbReference type="PubMed" id="12950348"/>
<dbReference type="DOI" id="10.1046/j.1365-2230.2003.01344.x"/>
</citation>
<scope>INVOLVEMENT IN BRSS</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2005" name="Br. J. Dermatol." volume="153" first="1213" last="1215">
<title>Two novel CYLD gene mutations in Chinese families with trichoepithelioma and a literature review of 16 families with trichoepithelioma reported in China.</title>
<authorList>
<person name="Liang Y.H."/>
<person name="Gao M."/>
<person name="Sun L.D."/>
<person name="Liu L.J."/>
<person name="Cui Y."/>
<person name="Yang S."/>
<person name="Fan X."/>
<person name="Wang J."/>
<person name="Xiao F.L."/>
<person name="Zhang X.J."/>
</authorList>
<dbReference type="PubMed" id="16307661"/>
<dbReference type="DOI" id="10.1111/j.1365-2133.2005.06960.x"/>
</citation>
<scope>INVOLVEMENT IN MFT1</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2005" name="J. Invest. Dermatol." volume="124" first="919" last="920">
<title>Mutations in the CYLD gene in Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma: lack of genotype-phenotype correlation.</title>
<authorList>
<person name="Bowen S."/>
<person name="Gill M."/>
<person name="Lee D.A."/>
<person name="Fisher G."/>
<person name="Geronemus R.G."/>
<person name="Vazquez M.E."/>
<person name="Celebi J.T."/>
</authorList>
<dbReference type="PubMed" id="15854031"/>
<dbReference type="DOI" id="10.1111/j.0022-202x.2005.23688.x"/>
</citation>
<scope>INVOLVEMENT IN BRSS</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2006" name="Clin. Genet." volume="70" first="246" last="249">
<title>CYLD mutations underlie Brooke-Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma syndromes.</title>
<authorList>
<person name="Young A.L."/>
<person name="Kellermayer R."/>
<person name="Szigeti R."/>
<person name="Teszas A."/>
<person name="Azmi S."/>
<person name="Celebi J.T."/>
</authorList>
<dbReference type="PubMed" id="16922728"/>
<dbReference type="DOI" id="10.1111/j.1399-0004.2006.00667.x"/>
</citation>
<scope>INVOLVEMENT IN FCYL</scope>
<scope>INVOLVEMENT IN MFT1</scope>
</reference>
<reference key="26">
<citation type="journal article" date="2015" name="Cell Rep." volume="13" first="2258" last="2272">
<title>LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes.</title>
<authorList>
<person name="Draber P."/>
<person name="Kupka S."/>
<person name="Reichert M."/>
<person name="Draberova H."/>
<person name="Lafont E."/>
<person name="de Miguel D."/>
<person name="Spilgies L."/>
<person name="Surinova S."/>
<person name="Taraborrelli L."/>
<person name="Hartwig T."/>
<person name="Rieser E."/>
<person name="Martino L."/>
<person name="Rittinger K."/>
<person name="Walczak H."/>
</authorList>
<dbReference type="PubMed" id="26670046"/>
<dbReference type="DOI" id="10.1016/j.celrep.2015.11.009"/>
</citation>
<scope>FUNCTION</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2016" name="EMBO J." volume="35" first="1868" last="1884">
<title>SPATA2 links CYLD to the TNF-alpha receptor signaling complex and modulates the receptor signaling outcomes.</title>
<authorList>
<person name="Wagner S.A."/>
<person name="Satpathy S."/>
<person name="Beli P."/>
<person name="Choudhary C."/>
</authorList>
<dbReference type="PubMed" id="27307491"/>
<dbReference type="DOI" id="10.15252/embj.201694300"/>
</citation>
<scope>INTERACTION WITH SPATA2</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2016" name="EMBO Rep." volume="17" first="1485" last="1497">
<title>SPATA2 promotes CYLD activity and regulates TNF-induced NF-kappaB signaling and cell death.</title>
<authorList>
<person name="Schlicher L."/>
<person name="Wissler M."/>
<person name="Preiss F."/>
<person name="Brauns-Schubert P."/>
<person name="Jakob C."/>
<person name="Dumit V."/>
<person name="Borner C."/>
<person name="Dengjel J."/>
<person name="Maurer U."/>
</authorList>
<dbReference type="PubMed" id="27458237"/>
<dbReference type="DOI" id="10.15252/embr.201642592"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>INTERACTION WITH SPATA2</scope>
<scope>MUTAGENESIS OF CYS-601</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2016" name="Cell Rep." volume="16" first="2271" last="2280">
<title>SPATA2-Mediated Binding of CYLD to HOIP Enables CYLD Recruitment to Signaling Complexes.</title>
<authorList>
<person name="Kupka S."/>
<person name="De Miguel D."/>
<person name="Draber P."/>
<person name="Martino L."/>
<person name="Surinova S."/>
<person name="Rittinger K."/>
<person name="Walczak H."/>
</authorList>
<dbReference type="PubMed" id="27545878"/>
<dbReference type="DOI" id="10.1016/j.celrep.2016.07.086"/>
</citation>
<scope>INTERACTION WITH SPATA2</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2016" name="Cell Rep." volume="14" first="2846" last="2858">
<title>CYLD limits Lys63- and Met1-linked ubiquitin at receptor complexes to regulate innate immune signaling.</title>
<authorList>
<person name="Hrdinka M."/>
<person name="Fiil B.K."/>
<person name="Zucca M."/>
<person name="Leske D."/>
<person name="Bagola K."/>
<person name="Yabal M."/>
<person name="Elliott P.R."/>
<person name="Damgaard R.B."/>
<person name="Komander D."/>
<person name="Jost P.J."/>
<person name="Gyrd-Hansen M."/>
</authorList>
<dbReference type="PubMed" id="26997266"/>
<dbReference type="DOI" id="10.1016/j.celrep.2016.02.062"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH RNF31</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2016" name="Mol. Cell" volume="63" first="990" last="1005">
<title>SPATA2 links CYLD to LUBAC, activates CYLD, and controls LUBAC signaling.</title>
<authorList>
<person name="Elliott P.R."/>
<person name="Leske D."/>
<person name="Hrdinka M."/>
<person name="Bagola K."/>
<person name="Fiil B.K."/>
<person name="McLaughlin S.H."/>
<person name="Wagstaff J."/>
<person name="Volkmar N."/>
<person name="Christianson J.C."/>
<person name="Kessler B.M."/>
<person name="Freund S.M."/>
<person name="Komander D."/>
<person name="Gyrd-Hansen M."/>
</authorList>
<dbReference type="PubMed" id="27591049"/>
<dbReference type="DOI" id="10.1016/j.molcel.2016.08.001"/>
</citation>
<scope>FUNCTION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>INTERACTION WITH SPATA2</scope>
<scope>MUTAGENESIS OF LEU-622</scope>
</reference>
<reference key="32">
<citation type="journal article" date="2018" name="Nat. Med." volume="24" first="213" last="223">
<title>The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.</title>
<authorList>
<person name="Ji Y.X."/>
<person name="Huang Z."/>
<person name="Yang X."/>
<person name="Wang X."/>
<person name="Zhao L.P."/>
<person name="Wang P.X."/>
<person name="Zhang X.J."/>
<person name="Alves-Bezerra M."/>
<person name="Cai L."/>
<person name="Zhang P."/>
<person name="Lu Y.X."/>
<person name="Bai L."/>
<person name="Gao M.M."/>
<person name="Zhao H."/>
<person name="Tian S."/>
<person name="Wang Y."/>
<person name="Huang Z.X."/>
<person name="Zhu X.Y."/>
<person name="Zhang Y."/>
<person name="Gong J."/>
<person name="She Z.G."/>
<person name="Li F."/>
<person name="Cohen D.E."/>
<person name="Li H."/>
</authorList>
<dbReference type="PubMed" id="29291351"/>
<dbReference type="DOI" id="10.1038/nm.4461"/>
</citation>
<scope>FUNCTION</scope>
<scope>TISSUE SPECIFICITY</scope>
<scope>UBIQUITINATION</scope>
</reference>
<reference key="33">
<citation type="journal article" date="2004" name="Structure" volume="12" first="1719" last="1728">
<title>The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma.</title>
<authorList>
<person name="Saito K."/>
<person name="Kigawa T."/>
<person name="Koshiba S."/>
<person name="Sato K."/>
<person name="Matsuo Y."/>
<person name="Sakamoto A."/>
<person name="Takagi T."/>
<person name="Shirouzu M."/>
<person name="Yabuki T."/>
<person name="Nunokawa E."/>
<person name="Seki E."/>
<person name="Matsuda T."/>
<person name="Aoki M."/>
<person name="Miyata Y."/>
<person name="Hirakawa N."/>
<person name="Inoue M."/>
<person name="Terada T."/>
<person name="Nagase T."/>
<person name="Kikuno R."/>
<person name="Nakayama M."/>
<person name="Ohara O."/>
<person name="Tanaka A."/>
<person name="Yokoyama S."/>
</authorList>
<dbReference type="PubMed" id="15341735"/>
<dbReference type="DOI" id="10.1016/j.str.2004.07.012"/>
</citation>
<scope>STRUCTURE BY NMR OF 460-550</scope>
<scope>INTERACTION WITH IKBKG</scope>
</reference>
<reference key="34">
<citation type="submission" date="2004-11" db="PDB data bank">
<title>Solution structure of the 1st and 2nd CAP-Gly domains in human cylindromatosis tumor suppressor CYLD.</title>
<authorList>
<consortium name="RIKEN structural genomics initiative (RSGI)"/>
</authorList>
</citation>
<scope>STRUCTURE BY NMR OF 125-304</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2008" name="Mol. Cell" volume="29" first="451" last="464">
<title>The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.</title>
<authorList>
<person name="Komander D."/>
<person name="Lord C.J."/>
<person name="Scheel H."/>
<person name="Swift S."/>
<person name="Hofmann K."/>
<person name="Ashworth A."/>
<person name="Barford D."/>
</authorList>
<dbReference type="PubMed" id="18313383"/>
<dbReference type="DOI" id="10.1016/j.molcel.2007.12.018"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 583-956 IN COMPLEX WITH ZINC IONS</scope>
<scope>FUNCTION</scope>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF CYS-601</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2003" name="J. Invest. Dermatol." volume="121" first="732" last="734">
<title>A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome.</title>
<authorList>
<person name="Hu G."/>
<person name="Oender M."/>
<person name="Gill M."/>
<person name="Aksakal B."/>
<person name="Oeztas M."/>
<person name="Guerer M.A."/>
<person name="Celebi J.T."/>
</authorList>
<dbReference type="PubMed" id="14632188"/>
<dbReference type="DOI" id="10.1046/j.1523-1747.2003.12514.x"/>
</citation>
<scope>VARIANT MFT1 GLY-747</scope>
<scope>VARIANT BRSS GLY-747</scope>
</reference>
<comment type="function">
<text evidence="7 12 13 14 23 24 25 26 27 28 29 31 32 34 36 37">Deubiquitinase that specifically cleaves 'Lys-63'- and linear 'Met-1'-linked polyubiquitin chains and is involved in NF-kappa-B activation and TNF-alpha-induced necroptosis (PubMed:18636086, PubMed:26670046, PubMed:27458237, PubMed:26997266, PubMed:27591049, PubMed:29291351, PubMed:18313383). Plays an important role in the regulation of pathways leading to NF-kappa-B activation (PubMed:12917689, PubMed:12917691). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B (PubMed:18636086). Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells (By similarity). Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane; this process does not depend on NF-kappa-B activation (By similarity). Ability to remove linear ('Met-1'-linked) polyubiquitin chains regulates innate immunity and TNF-alpha-induced necroptosis: recruited to the LUBAC complex via interaction with SPATA2 and restricts linear polyubiquitin formation on target proteins (PubMed:26997266, PubMed:26670046, PubMed:27458237, PubMed:27591049). Regulates innate immunity by restricting linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26997266). Involved in TNF-alpha-induced necroptosis by removing linear ('Met-1'-linked) polyubiquitin chains from RIPK1, thereby regulating the kinase activity of RIPK1 (By similarity). Removes 'Lys-63' linked polyubiquitin chain of MAP3K7, which inhibits phosphorylation and blocks downstream activation of the JNK-p38 kinase cascades (PubMed:29291351).</text>
</comment>
<comment type="catalytic activity">
<reaction evidence="25 34 36">
<text>Thiol-dependent hydrolysis of ester, thioester, amide, peptide and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-residue protein attached to proteins as an intracellular targeting signal).</text>
<dbReference type="EC" id="3.4.19.12"/>
</reaction>
</comment>
<comment type="activity regulation">
<text evidence="20">Inhibited by phosphorylation at serine residues.</text>
</comment>
<comment type="subunit">
<text evidence="7 12 13 14 17 18 23 26 27 29 30 32 33 34 35 36">Interacts (via CAP-Gly domain) with IKBKG/NEMO (via proline-rich C-terminal region) (PubMed:12917689, PubMed:12917690, PubMed:12917691, PubMed:15341735). Interacts with TRAF2 and TRIP (PubMed:12917691, PubMed:14676304). Interacts with PLK1, DVL1, DVL3, MAVS, TBK1, IKKE and DDX58 (PubMed:17495026, PubMed:18636086, PubMed:20227366). Interacts (via CAP-Gly domain) with microtubules (PubMed:19893491). Interacts with HDAC6 and BCL3 (PubMed:19893491). Interacts with MAP3K7 (By similarity). Identified in a complex with TRAF6 and SQSTM1 (By similarity). Interacts with CEP350 (PubMed:25134987). Interacts with RNF31; the interaction is indirect and is mediated via SPATA2 (PubMed:26997266). Interacts with SPATA2 (via the PUB domain); the interaction is direct and recruits CYLD to the LUBAC complex, thereby regulating TNF-alpha-induced necroptosis (PubMed:27307491, PubMed:27458237, PubMed:27545878, PubMed:27591049).</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2117940">
<id>Q9NQC7</id>
</interactant>
<interactant intactId="EBI-995350">
<id>O95786</id>
<label>DDX58</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2117940">
<id>Q9NQC7</id>
</interactant>
<interactant intactId="EBI-301697">
<id>Q9UBN7</id>
<label>HDAC6</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2117940">
<id>Q9NQC7</id>
</interactant>
<interactant intactId="EBI-1564678">
<id>Q96J02</id>
<label>ITCH</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2117940">
<id>Q9NQC7</id>
</interactant>
<interactant intactId="EBI-6672198">
<id>Q96J02-2</id>
<label>ITCH</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-2117940">
<id>Q9NQC7</id>
</interactant>
<interactant intactId="EBI-302552">
<id>Q71U36</id>
<label>TUBA1A</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>6</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="25">Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasm</location>
<location>Perinuclear region</location>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasm</location>
<location>Cytoskeleton</location>
</subcellularLocation>
<subcellularLocation>
<location>Cell membrane</location>
<topology>Peripheral membrane protein</topology>
<orientation>Cytoplasmic side</orientation>
</subcellularLocation>
<subcellularLocation>
<location evidence="30">Cytoplasm</location>
<location evidence="30">Cytoskeleton</location>
<location evidence="30">Microtubule organizing center</location>
<location evidence="30">Centrosome</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="30">Cytoplasm</location>
<location evidence="30">Cytoskeleton</location>
<location evidence="30">Spindle</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="7">Cytoplasm</location>
<location evidence="7">Cytoskeleton</location>
<location evidence="7">Cilium basal body</location>
</subcellularLocation>
<text evidence="7 30">Detected at the microtubule cytoskeleton during interphase. Detected at the midbody during telophase. During metaphase, it remains localized to the centrosome but is also present along the spindle (PubMed:25134987).</text>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>Q9NQC7-1</id>
<name>1</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>Q9NQC7-2</id>
<name>2</name>
<sequence type="described" ref="VSP_011277"/>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="10 37">Detected in fetal brain, testis, and skeletal muscle, and at a lower level in adult brain, leukocytes, liver, heart, kidney, spleen, ovary and lung. Isoform 2 is found in all tissues except kidney.</text>
</comment>
<comment type="PTM">
<text evidence="37">Ubiquitinated. Polyubiquitinated in hepatocytes treated with palmitic acid. Ubiquitination is mediated by E3 ligase TRIM47 and leads to proteasomal degradation.</text>
</comment>
<comment type="PTM">
<text evidence="20">Phosphorylated on several serine residues by IKKA and/or IKKB in response to immune stimuli. Phosphorylation requires IKBKG. Phosphorylation abolishes TRAF2 deubiquitination, interferes with the activation of Jun kinases, and strongly reduces CD40-dependent gene activation by NF-kappa-B.</text>
</comment>
<comment type="disease" evidence="11 22">
<disease id="DI-01564">
<name>Cylindromatosis, familial</name>
<acronym>FCYL</acronym>
<description>A disorder characterized by multiple skin tumors that develop from skin appendages, such as hair follicles and sweat glands. Affected individuals typically develop large numbers of tumors called cylindromas that arise predominantly in hairy parts of the body with approximately 90% on the head and neck. In severely affected individuals, cylindromas may combine into a confluent mass which may ulcerate or become infected (turban tumor syndrome). Individuals with familial cylindromatosis occasionally develop other types of tumors including spiradenomas that begin in sweat glands, and trichoepitheliomas arising from hair follicles.</description>
<dbReference type="MIM" id="132700"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="16 21 22">
<disease id="DI-02007">
<name>Multiple familial trichoepithelioma 1</name>
<acronym>MFT1</acronym>
<description>Autosomal dominant dermatosis characterized by the presence of many skin tumors predominantly on the face. Since histologic examination shows dermal aggregates of basaloid cells with connection to or differentiation toward hair follicles, this disorder has been thought to represent a benign hamartoma of the pilosebaceous apparatus. Trichoepitheliomas can degenerate into basal cell carcinoma.</description>
<dbReference type="MIM" id="601606"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="11 15 16 19">
<disease id="DI-00201">
<name>Brooke-Spiegler syndrome</name>
<acronym>BRSS</acronym>
<description>An autosomal dominant disorder characterized by the appearance of multiple skin appendage tumors such as cylindroma, trichoepithelioma, and spiradenoma. These tumors are typically located in the head and neck region, appear in early adulthood, and gradually increase in size and number throughout life.</description>
<dbReference type="MIM" id="605041"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="41">Belongs to the peptidase C19 family.</text>
</comment>
<comment type="sequence caution" evidence="41">
<conflict type="frameshift">
<sequence resource="EMBL-CDS" id="AAF29029" version="1"/>
</conflict>
</comment>
<comment type="sequence caution" evidence="41">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="BAA74872" version="2"/>
</conflict>
<text>Extended N-terminus.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/CYLDID40232ch16q12.html"/>
</comment>
<dbReference type="EC" id="3.4.19.12" evidence="25 34 36"/>
<dbReference type="EMBL" id="AJ250014">
<property type="protein sequence ID" value="CAB93533.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AB020656">
<property type="protein sequence ID" value="BAA74872.2"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC012342">
<property type="protein sequence ID" value="AAH12342.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF161542">
<property type="protein sequence ID" value="AAF29029.1"/>
<property type="status" value="ALT_FRAME"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS42164.1">
<molecule id="Q9NQC7-2"/>
</dbReference>
<dbReference type="CCDS" id="CCDS45482.1">
<molecule id="Q9NQC7-1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001035814.1">
<molecule id="Q9NQC7-2"/>
<property type="nucleotide sequence ID" value="NM_001042355.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001035877.1">
<molecule id="Q9NQC7-2"/>
<property type="nucleotide sequence ID" value="NM_001042412.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_056062.1">
<molecule id="Q9NQC7-1"/>
<property type="nucleotide sequence ID" value="NM_015247.2"/>
</dbReference>
<dbReference type="RefSeq" id="XP_016878467.1">
<molecule id="Q9NQC7-2"/>
<property type="nucleotide sequence ID" value="XM_017022978.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_016878469.1">
<molecule id="Q9NQC7-2"/>
<property type="nucleotide sequence ID" value="XM_017022980.1"/>
</dbReference>
<dbReference type="PDB" id="1IXD">
<property type="method" value="NMR"/>
<property type="chains" value="A=460-550"/>
</dbReference>
<dbReference type="PDB" id="1WHL">
<property type="method" value="NMR"/>
<property type="chains" value="A=125-206"/>
</dbReference>
<dbReference type="PDB" id="1WHM">
<property type="method" value="NMR"/>
<property type="chains" value="A=228-304"/>
</dbReference>
<dbReference type="PDB" id="2VHF">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A/B=583-956"/>
</dbReference>
<dbReference type="PDBsum" id="1IXD"/>
<dbReference type="PDBsum" id="1WHL"/>
<dbReference type="PDBsum" id="1WHM"/>
<dbReference type="PDBsum" id="2VHF"/>
<dbReference type="SMR" id="Q9NQC7"/>
<dbReference type="BioGRID" id="107920">
<property type="interactions" value="772"/>
</dbReference>
<dbReference type="CORUM" id="Q9NQC7"/>
<dbReference type="IntAct" id="Q9NQC7">
<property type="interactions" value="56"/>
</dbReference>
<dbReference type="MINT" id="Q9NQC7"/>
<dbReference type="STRING" id="9606.ENSP00000392025"/>
<dbReference type="MEROPS" id="C67.001"/>
<dbReference type="iPTMnet" id="Q9NQC7"/>
<dbReference type="PhosphoSitePlus" id="Q9NQC7"/>
<dbReference type="BioMuta" id="CYLD"/>
<dbReference type="DMDM" id="51316104"/>
<dbReference type="jPOST" id="Q9NQC7"/>
<dbReference type="MassIVE" id="Q9NQC7"/>
<dbReference type="MaxQB" id="Q9NQC7"/>
<dbReference type="PaxDb" id="Q9NQC7"/>
<dbReference type="PeptideAtlas" id="Q9NQC7"/>
<dbReference type="PRIDE" id="Q9NQC7"/>
<dbReference type="ProteomicsDB" id="82139">
<molecule id="Q9NQC7-1"/>
</dbReference>
<dbReference type="ProteomicsDB" id="82140">
<molecule id="Q9NQC7-2"/>
</dbReference>
<dbReference type="Antibodypedia" id="3193">
<property type="antibodies" value="295 antibodies"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000311559">
<molecule id="Q9NQC7-1"/>
<property type="protein sequence ID" value="ENSP00000308928"/>
<property type="gene ID" value="ENSG00000083799"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000398568">
<molecule id="Q9NQC7-2"/>
<property type="protein sequence ID" value="ENSP00000381574"/>
<property type="gene ID" value="ENSG00000083799"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000427738">
<molecule id="Q9NQC7-1"/>
<property type="protein sequence ID" value="ENSP00000392025"/>
<property type="gene ID" value="ENSG00000083799"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000564326">
<molecule id="Q9NQC7-2"/>
<property type="protein sequence ID" value="ENSP00000454515"/>
<property type="gene ID" value="ENSG00000083799"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000569418">
<molecule id="Q9NQC7-2"/>
<property type="protein sequence ID" value="ENSP00000457576"/>
<property type="gene ID" value="ENSG00000083799"/>
</dbReference>
<dbReference type="GeneID" id="1540"/>
<dbReference type="KEGG" id="hsa:1540"/>
<dbReference type="UCSC" id="uc002egq.2">
<molecule id="Q9NQC7-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="1540"/>
<dbReference type="DisGeNET" id="1540"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000083799.17"/>
<dbReference type="GeneCards" id="CYLD"/>
<dbReference type="HGNC" id="HGNC:2584">
<property type="gene designation" value="CYLD"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000083799">
<property type="expression patterns" value="Low tissue specificity"/>
</dbReference>
<dbReference type="MalaCards" id="CYLD"/>
<dbReference type="MIM" id="132700">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="601606">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="605018">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="605041">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_Q9NQC7"/>
<dbReference type="OpenTargets" id="ENSG00000083799"/>
<dbReference type="Orphanet" id="211">
<property type="disease" value="Familial cylindromatosis"/>
</dbReference>
<dbReference type="Orphanet" id="867">
<property type="disease" value="Familial multiple trichoepithelioma"/>
</dbReference>
<dbReference type="PharmGKB" id="PA27084"/>
<dbReference type="eggNOG" id="KOG3556">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00390000018123"/>
<dbReference type="InParanoid" id="Q9NQC7"/>
<dbReference type="KO" id="K08601"/>
<dbReference type="OMA" id="FNGVQLC"/>
<dbReference type="OrthoDB" id="119442at2759"/>
<dbReference type="PhylomeDB" id="Q9NQC7"/>
<dbReference type="TreeFam" id="TF318734"/>
<dbReference type="PathwayCommons" id="Q9NQC7"/>
<dbReference type="Reactome" id="R-HSA-168638">
<property type="pathway name" value="NOD1/2 Signaling Pathway"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5357786">
<property type="pathway name" value="TNFR1-induced proapoptotic signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5357905">
<property type="pathway name" value="Regulation of TNFR1 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5357956">
<property type="pathway name" value="TNFR1-induced NFkappaB signaling pathway"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5689880">
<property type="pathway name" value="Ub-specific processing proteases"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-936440">
<property type="pathway name" value="Negative regulators of DDX58/IFIH1 signaling"/>
</dbReference>
<dbReference type="SIGNOR" id="Q9NQC7"/>
<dbReference type="BioGRID-ORCS" id="1540">
<property type="hits" value="17 hits in 876 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="CYLD">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="Q9NQC7"/>
<dbReference type="GeneWiki" id="CYLD_(gene)"/>
<dbReference type="GenomeRNAi" id="1540"/>
<dbReference type="Pharos" id="Q9NQC7">
<property type="development level" value="Tbio"/>
</dbReference>
<dbReference type="PRO" id="PR:Q9NQC7"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 16"/>
</dbReference>
<dbReference type="RNAct" id="Q9NQC7">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000083799">
<property type="expression patterns" value="Expressed in caudate nucleus and 243 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="Q9NQC7">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="Q9NQC7">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005813">
<property type="term" value="C:centrosome"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0036064">
<property type="term" value="C:ciliary basal body"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0097542">
<property type="term" value="C:ciliary tip"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031234">
<property type="term" value="C:extrinsic component of cytoplasmic side of plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005874">
<property type="term" value="C:microtubule"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0048471">
<property type="term" value="C:perinuclear region of cytoplasm"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005819">
<property type="term" value="C:spindle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1990380">
<property type="term" value="F:Lys48-specific deubiquitinase activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0061578">
<property type="term" value="F:Lys63-specific deubiquitinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070064">
<property type="term" value="F:proline-rich region binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0019901">
<property type="term" value="F:protein kinase binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0004843">
<property type="term" value="F:thiol-dependent ubiquitin-specific protease activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0036459">
<property type="term" value="F:thiol-dependent ubiquitinyl hydrolase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0008270">
<property type="term" value="F:zinc ion binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043369">
<property type="term" value="P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0007049">
<property type="term" value="P:cell cycle"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0048872">
<property type="term" value="P:homeostasis of number of cells"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0045087">
<property type="term" value="P:innate immune response"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070266">
<property type="term" value="P:necroptotic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0090090">
<property type="term" value="P:negative regulation of canonical Wnt signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046329">
<property type="term" value="P:negative regulation of JNK cascade"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032088">
<property type="term" value="P:negative regulation of NF-kappaB transcription factor activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1901223">
<property type="term" value="P:negative regulation of NIK/NF-kappaB signaling"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1903753">
<property type="term" value="P:negative regulation of p38MAPK cascade"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0032480">
<property type="term" value="P:negative regulation of type I interferon production"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0070423">
<property type="term" value="P:nucleotide-binding oligomerization domain containing signaling pathway"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:1903829">
<property type="term" value="P:positive regulation of cellular protein localization"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:2001238">
<property type="term" value="P:positive regulation of extrinsic apoptotic signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045582">
<property type="term" value="P:positive regulation of T cell differentiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0050862">
<property type="term" value="P:positive regulation of T cell receptor signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0016579">
<property type="term" value="P:protein deubiquitination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070536">
<property type="term" value="P:protein K63-linked deubiquitination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1990108">
<property type="term" value="P:protein linear deubiquitination"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0045577">
<property type="term" value="P:regulation of B cell differentiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1902017">
<property type="term" value="P:regulation of cilium assembly"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0050727">
<property type="term" value="P:regulation of inflammatory response"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2001242">
<property type="term" value="P:regulation of intrinsic apoptotic signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070507">
<property type="term" value="P:regulation of microtubule cytoskeleton organization"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007346">
<property type="term" value="P:regulation of mitotic cell cycle"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0060544">
<property type="term" value="P:regulation of necroptotic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043393">
<property type="term" value="P:regulation of protein binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0010803">
<property type="term" value="P:regulation of tumor necrosis factor-mediated signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1901026">
<property type="term" value="P:ripoptosome assembly involved in necroptotic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006511">
<property type="term" value="P:ubiquitin-dependent protein catabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0016055">
<property type="term" value="P:Wnt signaling pathway"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="Gene3D" id="2.30.30.190">
<property type="match status" value="3"/>
</dbReference>
<dbReference type="InterPro" id="IPR036859">
<property type="entry name" value="CAP-Gly_dom_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR000938">
<property type="entry name" value="CAP-Gly_domain"/>
</dbReference>
<dbReference type="InterPro" id="IPR038765">
<property type="entry name" value="Papain-like_cys_pep_sf"/>
</dbReference>
<dbReference type="InterPro" id="IPR001394">
<property type="entry name" value="Peptidase_C19_UCH"/>
</dbReference>
<dbReference type="InterPro" id="IPR018200">
<property type="entry name" value="USP_CS"/>
</dbReference>
<dbReference type="InterPro" id="IPR028889">
<property type="entry name" value="USP_dom"/>
</dbReference>
<dbReference type="Pfam" id="PF01302">
<property type="entry name" value="CAP_GLY"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="Pfam" id="PF00443">
<property type="entry name" value="UCH"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SMART" id="SM01052">
<property type="entry name" value="CAP_GLY"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF54001">
<property type="entry name" value="SSF54001"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF74924">
<property type="entry name" value="SSF74924"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="PROSITE" id="PS00845">
<property type="entry name" value="CAP_GLY_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50245">
<property type="entry name" value="CAP_GLY_2"/>
<property type="match status" value="2"/>
</dbReference>
<dbReference type="PROSITE" id="PS00972">
<property type="entry name" value="USP_1"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50235">
<property type="entry name" value="USP_3"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0131">Cell cycle</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0966">Cell projection</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0206">Cytoskeleton</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0378">Hydrolase</keyword>
<keyword id="KW-0391">Immunity</keyword>
<keyword id="KW-0399">Innate immunity</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0493">Microtubule</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0645">Protease</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0788">Thiol protease</keyword>
<keyword id="KW-0043">Tumor suppressor</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<keyword id="KW-0833">Ubl conjugation pathway</keyword>
<keyword id="KW-0879">Wnt signaling pathway</keyword>
<keyword id="KW-0862">Zinc</keyword>
<feature type="chain" description="Ubiquitin carboxyl-terminal hydrolase CYLD" id="PRO_0000080698">
<location>
<begin position="1"/>
<end position="956"/>
</location>
</feature>
<feature type="domain" description="CAP-Gly 1" evidence="8">
<location>
<begin position="153"/>
<end position="198"/>
</location>
</feature>
<feature type="domain" description="CAP-Gly 2" evidence="8">
<location>
<begin position="253"/>
<end position="286"/>
</location>
</feature>
<feature type="domain" description="CAP-Gly 3" evidence="8">
<location>
<begin position="492"/>
<end position="535"/>
</location>
</feature>
<feature type="domain" description="USP">
<location>
<begin position="592"/>
<end position="950"/>
</location>
</feature>
<feature type="region of interest" description="Interaction with TRIP" evidence="17">
<location>
<begin position="106"/>
<end position="593"/>
</location>
</feature>
<feature type="region of interest" description="Interaction with TRAF2">
<location>
<begin position="394"/>
<end position="469"/>
</location>
</feature>
<feature type="region of interest" description="Interaction with IKBKG/NEMO" evidence="18">
<location>
<begin position="470"/>
<end position="554"/>
</location>
</feature>
<feature type="region of interest" description="B-box" evidence="25 36">
<location>
<begin position="781"/>
<end position="833"/>
</location>
</feature>
<feature type="active site" description="Nucleophile" evidence="9 25">
<location>
<position position="601"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="42">
<location>
<position position="871"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="788"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="791"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="799"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="802"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="817"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 1">
<location>
<position position="820"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="825"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc 2">
<location>
<position position="833"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="6">
<location>
<position position="387"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5 20">
<location>
<position position="418"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5">
<location>
<position position="422"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_011277" evidence="38 40">
<location>
<begin position="305"/>
<end position="307"/>
</location>
</feature>
<feature type="sequence variant" description="In MFT1 and BRSS; dbSNP:rs121908389." id="VAR_045967" evidence="16">
<original>E</original>
<variation>G</variation>
<location>
<position position="747"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduced phosphorylation; when associated with A-422; A-432 and A-436. Loss of phosphorylation; when associated with A-422; A-432; A-436; A-439; A-441 and A-444." evidence="20">
<original>S</original>
<variation>A</variation>
<location>
<position position="418"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes deubiquitination of TRAF2; when associated with E-422; E-432; E-436; E-439; E-441 and E-444." evidence="20">
<original>S</original>
<variation>E</variation>
<location>
<position position="418"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduced phosphorylation; when associated with A-418; A-432 and A-436. Loss of phosphorylation; when associated with A-418; A-432; A-436; A-439; A-441 and A-444." evidence="20">
<original>S</original>
<variation>A</variation>
<location>
<position position="422"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes deubiquitination of TRAF2; when associated with E-418; E-432; E-436; E-439; E-441 and E-444." evidence="20">
<original>S</original>
<variation>E</variation>
<location>
<position position="422"/>
</location>
</feature>
<feature type="mutagenesis site" description="Slightly reduced phosphorylation; when associated with A-436. Reduced phosphorylation; when associated with A-418; A-422 and A-436. Loss of phosphorylation; when associated with A-418; A-422; A-436; A-439; A-441 and A-444." evidence="20">
<original>S</original>
<variation>A</variation>
<location>
<position position="432"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-436; E-439; E-441 and E-444." evidence="20">
<original>S</original>
<variation>E</variation>
<location>
<position position="432"/>
</location>
</feature>
<feature type="mutagenesis site" description="Slightly reduced phosphorylation; when associated with A-432. Reduced phosphorylation; when associated with A-418; A-422 and A-432. Loss of phosphorylation; when associated with A-418; A-422; A-432; A-439; A-441 and A-444." evidence="20">
<original>S</original>
<variation>A</variation>
<location>
<position position="436"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-439; E-441 and E-444." evidence="20">
<original>S</original>
<variation>E</variation>
<location>
<position position="436"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation; when associated with A-418; A-422; A-432; A-436; A-441 and A-444." evidence="20">
<original>S</original>
<variation>A</variation>
<location>
<position position="439"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-436; E-441 and E-444." evidence="20">
<original>S</original>
<variation>E</variation>
<location>
<position position="439"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation; when associated with A-418; A-422; A-432; A-436; A-439 and A-444." evidence="20">
<original>S</original>
<variation>A</variation>
<location>
<position position="441"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-436; E-439 and E-444." evidence="20">
<original>S</original>
<variation>E</variation>
<location>
<position position="441"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of phosphorylation; when associated with A-418; A-422; A-432; A-436; A-439 and A-441." evidence="20">
<original>S</original>
<variation>A</variation>
<location>
<position position="444"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes deubiquitination of TRAF2; when associated with E-418; E-422; E-432; E-436; E-439 and E-441." evidence="20">
<original>S</original>
<variation>E</variation>
<location>
<position position="444"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes binding to TRAF2." evidence="14">
<original>S</original>
<variation>A</variation>
<location>
<position position="457"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of deubiquitinating activity." evidence="12 13 23 25 34">
<original>C</original>
<variation>A</variation>
<variation>S</variation>
<location>
<position position="601"/>
</location>
</feature>
<feature type="mutagenesis site" description="Impaired interaction with SPATA2." evidence="36">
<original>L</original>
<variation>D</variation>
<location>
<position position="622"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of deubiquitinating activity." evidence="14">
<original>H</original>
<variation>N</variation>
<location>
<position position="871"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="130"/>
<end position="134"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="136"/>
<end position="139"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="141"/>
<end position="149"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="154"/>
<end position="157"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="163"/>
<end position="167"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="169"/>
<end position="171"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="191"/>
<end position="193"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="194"/>
<end position="197"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="199"/>
<end position="201"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="202"/>
<end position="204"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="235"/>
<end position="240"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="243"/>
<end position="253"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="259"/>
<end position="261"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="264"/>
<end position="272"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="278"/>
<end position="280"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="283"/>
<end position="285"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="293"/>
<end position="298"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="299"/>
<end position="301"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="302"/>
<end position="304"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="463"/>
<end position="465"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="466"/>
<end position="468"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="474"/>
<end position="478"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="480"/>
<end position="482"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="486"/>
<end position="492"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="495"/>
<end position="497"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="501"/>
<end position="508"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="514"/>
<end position="518"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="531"/>
<end position="535"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="536"/>
<end position="538"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="539"/>
<end position="541"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="584"/>
<end position="586"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="588"/>
<end position="591"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="601"/>
<end position="611"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="612"/>
<end position="614"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="615"/>
<end position="617"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="618"/>
<end position="622"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="633"/>
<end position="642"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="645"/>
<end position="650"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="652"/>
<end position="654"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="656"/>
<end position="669"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="682"/>
<end position="690"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="691"/>
<end position="694"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="699"/>
<end position="704"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="710"/>
<end position="713"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="730"/>
<end position="741"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="743"/>
<end position="747"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="750"/>
<end position="755"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="760"/>
<end position="764"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="773"/>
<end position="775"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="778"/>
<end position="780"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="781"/>
<end position="784"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="789"/>
<end position="791"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="800"/>
<end position="802"/>
</location>
</feature>
<feature type="turn" evidence="4">
<location>
<begin position="806"/>
<end position="811"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="818"/>
<end position="824"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="828"/>
<end position="830"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="844"/>
<end position="846"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="859"/>
<end position="868"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="871"/>
<end position="877"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="879"/>
<end position="881"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="885"/>
<end position="889"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="905"/>
<end position="908"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="911"/>
<end position="914"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="920"/>
<end position="925"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="928"/>
<end position="930"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="935"/>
<end position="940"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="944"/>
<end position="948"/>
</location>
</feature>
<feature type="helix" evidence="4">
<location>
<begin position="950"/>
<end position="952"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1IXD"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1WHL"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1WHM"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2VHF"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="23186163"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="24275569"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q80TQ2"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00045"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10092"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10835629"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12190880"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12917689"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12917690"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12917691"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12950348"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14632188"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14676304"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15341735"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15854031"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15870263"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16307661"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16922728"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17495026"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18222923"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18313383"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18636086"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19893491"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20194890"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20227366"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25134987"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26670046"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26997266"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27307491"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27458237"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27545878"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="27591049"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29291351"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="10048485"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="12917689"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="15489334"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000305"/>
<evidence key="42" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="18313383"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000312">
<source>
<dbReference type="HGNC" id="HGNC:2584"/>
</source>
</evidence>
<sequence length="956" mass="107316" checksum="01831F9A83424631" modified="2000-10-01" version="1">MSSGLWSQEKVTSPYWEERIFYLLLQECSVTDKQTQKLLKVPKGSIGQYIQDRSVGHSRIPSAKGKKNQIGLKILEQPHAVLFVDEKDVVEINEKFTELLLAITNCEERFSLFKNRNRLSKGLQIDVGCPVKVQLRSGEEKFPGVVRFRGPLLAERTVSGIFFGVELLEEGRGQGFTDGVYQGKQLFQCDEDCGVFVALDKLELIEDDDTALESDYAGPGDTMQVELPPLEINSRVSLKVGETIESGTVIFCDVLPGKESLGYFVGVDMDNPIGNWDGRFDGVQLCSFACVESTILLHINDIIPALSESVTQERRPPKLAFMSRGVGDKGSSSHNKPKATGSTSDPGNRNRSELFYTLNGSSVDSQPQSKSKNTWYIDEVAEDPAKSLTEISTDFDRSSPPLQPPPVNSLTTENRFHSLPFSLTKMPNTNGSIGHSPLSLSAQSVMEELNTAPVQESPPLAMPPGNSHGLEVGSLAEVKENPPFYGVIRWIGQPPGLNEVLAGLELEDECAGCTDGTFRGTRYFTCALKKALFVKLKSCRPDSRFASLQPVSNQIERCNSLAFGGYLSEVVEENTPPKMEKEGLEIMIGKKKGIQGHYNSCYLDSTLFCLFAFSSVLDTVLLRPKEKNDVEYYSETQELLRTEIVNPLRIYGYVCATKIMKLRKILEKVEAASGFTSEEKDPEEFLNILFHHILRVEPLLKIRSAGQKVQDCYFYQIFMEKNEKVGVPTIQQLLEWSFINSNLKFAEAPSCLIIQMPRFGKDFKLFKKIFPSLELNITDLLEDTPRQCRICGGLAMYECRECYDDPDISAGKIKQFCKTCNTQVHLHPKRLNHKYNPVSLPKDLPDWDWRHGCIPCQNMELFAVLCIETSHYVAFVKYGKDDSAWLFFDSMADRDGGQNGFNIPQVTPCPEVGEYLKMSLEDLHSLDSRRIQGCARRLLCDAYMCMYQSPTMSLYK</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

